BIOMAT Database Logo BIOMAT Database Logo

Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. 1992

J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Service of Medical Oncology, Hospital La Paz, Madrid, Spain.

A total of 170 febrile episodes in neutropenic patients with cancer were randomly assigned to be treated with piperacillin-amikacin or ceftazidime-amikacin. The overall response rates were similar in both groups (68 and 65%, respectively). Response rates for clinically or microbiologically documented episodes were 54.5% for piperacillin-amikacin and 58.8% for ceftazidime-amikacin. Response rates for gram-negative bacillary infections were 65 and 73%, respectively. There was also no difference for gram-positive infections (31 and 50%, respectively). The toxicities were also comparable and consisted of skin rashes, hypokalemia, and diarrhea. Vancomycin was added if the fever persisted 72 h after the beginning of therapy; it increased the response rates to 94% when used with piperacillin-amikacin and 92% when used with ceftazidime plus amikacin. Our results suggest that the combinations show similar global efficacies in the treatment of febrile episodes in cancer patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D010878 Piperacillin Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. AB-Piperacillin,Cl-227193,Pipcil,Pipera-Hameln,Piperacillin Curasan,Piperacillin Fresenius,Piperacillin Hexal,Piperacillin Monosodium Salt,Piperacillin Sodium,Piperacillin-Ratiopharm,Pipercillin,Pipracil,Pipril,T-1220,T1220,AB Piperacillin,Cl 227193,Cl227193,Curasan, Piperacillin,Monosodium Salt, Piperacillin,Pipera Hameln,Piperacillin Ratiopharm,Salt, Piperacillin Monosodium,Sodium, Piperacillin,T 1220
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer.
January 1991, Reviews of infectious diseases,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
July 1998, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
January 1993, Chemotherapy,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Piperacillin-tazobactum plus amikacin versus ceftazidime plus amikacin as empirical therapy for Fever in neutropenic patients with hematological malignancies.
September 2011, Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients.
July 1988, The American journal of medicine,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
March 1999, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia.
December 1990, British journal of haematology,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
November 1989, The American journal of medicine,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies.
January 1989, Acta clinica Belgica,
J Feliu, and A Artal, and M González Barón, and A Berrocal, and I Chacón, and M L García de Paredes, and E Espinosa, and A Ordóñez, and P Zamora, and J M Montero
[Cefmenoxime or piperacillin plus amikacin. A prospective randomized comparison of empiric antibiotic therapy of febrile granulocytopenic cancer patients].
March 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!